Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone for Conduct and Disruptive Behavior Disorders
NCT00676429Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Jul 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in conduct disorder (CD), oppositional defiant disorder (ODD) and Disruptive behavior disorders (DBD) comparing Ziprasidone with Placebo (2 arms). Primary endpoint: Nisonger Child Behavior Rating Form for typical IQ at 11 weeks. Started Jul 2006; status: completed.
02
Drugs
ziprasidone
03
Conditions
conduct disorder (CD)oppositional defiant disorder (ODD)Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on NCT00676429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676429.